Overview of Q3 2025 Results Compugen has released its third quarter 2025 results, alongside key data updates from the company’s oncology pipeline. The highlights focus on COM701, Company-backed clinical data presented at ESMO 2025, and the ongoing progress of the MAIA-ovarian platform trial. The quarterly update underscores Compugen’s strategic emphasis on translating scientific insights into…